Bayer Corporation

Carol A Miller

Meitak Teresa Yip

Chris Thomas Zimmerle

Hai-Hang Kuo

Koleen K Messenger

Dayaweera Wijesuriya

Disclosed is a method for determining the concentration of an analyte in a sample of body fluid. The method involves contacting the body fluid sample with a test strip containing mobile, labeled specific binding partner for the analyte, through which strip the test fluid, analyte and any complex formed by interaction of the analyte and labeled specific binding partner therefore can flow by capillarity. The strip contains at least one zone for capture of the labeled specific binding partner and at least one separate zone for retention of the analyte/labeled specific binding partner complex. By determining the magnitude of the signal from the detectable label in the capture zone(s) and retention zone(s) and determining a final response signal by correlating signals using an algorithm and number of zones chosen in a manner that provides a final response signal best suited for the particular assay, the concentration of the analyte can be determined with greater precision.

Device and method for obtaining clinically significant analyte ratios

Disclosed is a method for the determination of creatinine in urine which involves contacting a urine test sample with a reagent system containing Cu.sup.+2, a hydroperoxide and an oxidizible dye which provides a detectable response when oxidized in the presence of a pseudoperoxide. The reagent system also includes a buffer to maintain the urine's pH within the range of 6.6 to 8.0 and a chelating agent for the cupric ions to prevent oxidation of the dye in the absence of creatinine.

Growing community of inventors

Elkhart, IN, United States of America

Carol A Miller